Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting
Ovarian cancer (OC) is the eighth most common cancer among the female population and the most lethal of all the female reproductive system malignancies. Poly (ADP-ribose) polymerase inhibitors (PARPis) have reshaped the treatment scenario of metastatic OC in the maintenance setting post platinum-bas...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-09-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/16/9/1261 |
| _version_ | 1827724580435787776 |
|---|---|
| author | Mauro Francesco Pio Maiorano Brigida Anna Maiorano Annalucia Biancofiore Gennaro Cormio Evaristo Maiello |
| author_facet | Mauro Francesco Pio Maiorano Brigida Anna Maiorano Annalucia Biancofiore Gennaro Cormio Evaristo Maiello |
| author_sort | Mauro Francesco Pio Maiorano |
| collection | DOAJ |
| description | Ovarian cancer (OC) is the eighth most common cancer among the female population and the most lethal of all the female reproductive system malignancies. Poly (ADP-ribose) polymerase inhibitors (PARPis) have reshaped the treatment scenario of metastatic OC in the maintenance setting post platinum-based chemotherapy. Niraparib is the first Food and Drug Administration (FDA)- and European Medical Agency (EMA)-approved PARPi as maintenance therapy for platinum-sensitive OC, regardless of BReast CAncer gene (BRCA) status, in first-line patients, with a recent restriction to germline BRCA mutations in second-line patients. In this review, we comprehensively summarized the pharmacological properties of niraparib, alongside the efficacy and safety data of the main trials leading to the current approvals, and discussed the future development of this agent. |
| first_indexed | 2024-03-10T22:17:20Z |
| format | Article |
| id | doaj.art-d5e116fc4b1a481fa7f0248f57c0cdf6 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-10T22:17:20Z |
| publishDate | 2023-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-d5e116fc4b1a481fa7f0248f57c0cdf62023-11-19T12:24:49ZengMDPI AGPharmaceuticals1424-82472023-09-01169126110.3390/ph16091261Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated SettingMauro Francesco Pio Maiorano0Brigida Anna Maiorano1Annalucia Biancofiore2Gennaro Cormio3Evaristo Maiello4Obstetrics and Gynecology Unit, Department of Biomedical Sciences and Human Oncology, University of Bari “Aldo Moro”, 70126 Bari, ItalyOncology Unit, Casa Sollievo della Sofferenza IRCCS, 71013 San Giovanni Rotondo, ItalyPharmacy Unit, Casa Sollievo della Sofferenza IRCCS, 71013 San Giovanni Rotondo, ItalyGynecologic Oncology Unit, IRCCS Istituto Tumori “Giovanni Paolo II”, 70124 Bari, ItalyOncology Unit, Casa Sollievo della Sofferenza IRCCS, 71013 San Giovanni Rotondo, ItalyOvarian cancer (OC) is the eighth most common cancer among the female population and the most lethal of all the female reproductive system malignancies. Poly (ADP-ribose) polymerase inhibitors (PARPis) have reshaped the treatment scenario of metastatic OC in the maintenance setting post platinum-based chemotherapy. Niraparib is the first Food and Drug Administration (FDA)- and European Medical Agency (EMA)-approved PARPi as maintenance therapy for platinum-sensitive OC, regardless of BReast CAncer gene (BRCA) status, in first-line patients, with a recent restriction to germline BRCA mutations in second-line patients. In this review, we comprehensively summarized the pharmacological properties of niraparib, alongside the efficacy and safety data of the main trials leading to the current approvals, and discussed the future development of this agent.https://www.mdpi.com/1424-8247/16/9/1261niraparib (ZEJULA<sup>®</sup>)PARPovarian cancerBRCAtarget therapy |
| spellingShingle | Mauro Francesco Pio Maiorano Brigida Anna Maiorano Annalucia Biancofiore Gennaro Cormio Evaristo Maiello Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting Pharmaceuticals niraparib (ZEJULA<sup>®</sup>) PARP ovarian cancer BRCA target therapy |
| title | Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting |
| title_full | Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting |
| title_fullStr | Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting |
| title_full_unstemmed | Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting |
| title_short | Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting |
| title_sort | niraparib and advanced ovarian cancer a beacon in the non brca mutated setting |
| topic | niraparib (ZEJULA<sup>®</sup>) PARP ovarian cancer BRCA target therapy |
| url | https://www.mdpi.com/1424-8247/16/9/1261 |
| work_keys_str_mv | AT maurofrancescopiomaiorano niraparibandadvancedovariancancerabeaconinthenonbrcamutatedsetting AT brigidaannamaiorano niraparibandadvancedovariancancerabeaconinthenonbrcamutatedsetting AT annaluciabiancofiore niraparibandadvancedovariancancerabeaconinthenonbrcamutatedsetting AT gennarocormio niraparibandadvancedovariancancerabeaconinthenonbrcamutatedsetting AT evaristomaiello niraparibandadvancedovariancancerabeaconinthenonbrcamutatedsetting |